Development of Prophylactic Therapy as a Preventative Strategy to Reduce COVID-19 Infections

引起冠状病毒引起的疾病（COVID-19）的SARS - CoV-2的迅速和逐步传播，深刻影响了世界各地数十万人的健康，使国家卫生保健系统紧张，并严重影响了全球经济稳定。SARS-CoV2感染的机制是病毒必须与膜结合形式的血管紧张素转换酶2 （ACE2）结合，并由宿主细胞内化该复合物。认识到ACE2是冠状病毒的共受体，为开发新的预防策略提供了机会，可以阻断该酶或降低其表达，以防止在包括ACE2表达的组织（如口腔、鼻腔、肺和肠上皮）中进入细胞和SARS-CoV2感染。这些门户组织可能构成病毒进入宿主的最重要途径。利用人体衍生的口腔、气道和肠道组织三维模型，我们将评估针对ACE2通道的新型人类预防性nasa和口服产品的作用机制。我们的目标是通过战略性地部署抗病毒鼻喷雾剂和漱口水/漱口水组合来预防或阻断冠状病毒感染，这种组合可以预防性地预防COVID-19感染。我们打算利用我们两家合作公司提供的两项新技术（一氧化氮释放溶液NORS和高大麻二酚CBD提取物）产生新知识；单独或协同作为佐剂，以开发一种新的预防性广谱抗微生物策略来抑制SARS-CoV2和其他类似的细菌或病毒感染。所产生的知识将有助于为我们的两个合作伙伴提供必要的科学支持，为合成/制造战略提供信息，以便为加拿大人开发急需的新型预防COVID-19流行病的解决方案。

The rapid and progressive spread of SARS CoV-2 that causes coronavirus-induced disease (COVID-19) has profoundly affected the health of hundreds of thousands of people around the world, strained national health care systems and significantly affected global economic stability. The mechanism of SARS-CoV2 infection is the requisite binding of the virus to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) and internalization of the complex by the host cell. Recognition that ACE2 is the co-receptor for the coronavirus provides an opportunity to develop new preventative strategies to block the enzyme or reduce its expression to prevent cellular entry and SARS-CoV2 infection in tissues that include ACE2 expression such as oral, nasal, lung and intestinal epithelia. These gateway tissues likely constitute the most important routes of viral entry into the hosts. Using human derived 3D models of oral, airway and intestinal tissues, we will evaluate the mechanism of action of novel prophylactic nasa and oral products for humans which target ACE2 gateways. Our goal is to prevent or block coronavirus infection through the strategic deployment of an antiviral nasal spray and mouthwash/gargle combination that can be used in tandem prophylactically to prevent COVID-19 infection. We intend to generate new knowledge on the use of two new technologies provided by our two collaborating companies (Nitric Oxide Releasing Solution NORS and High-Cannabidiol CBD extracts); both separately and synergistically as adjuvants, in order to develop a new preventative broad spectrum anti-microbial strategy to inhibit SARS-CoV2 and other similar bacterial or viral infections. The knowledge generated will help provide the necessary scientific support required to inform the synthesis/manufacturing strategy for both of our collaborating partners in order to develop much needed novel preventative solutions to the COVID-19 epidemic for Canadians.